Riddell, S.R. and Greenberg, P.D., 1995. Principles for adoptive T cell therapy of human viral diseases. Annual review of immunology, 13(1), pp.545-586.doi:10.1146/annurev.iy.13.040195.002553
Feltkamp, M.C., Smits, H.L., Vierboom, M.P., Minnaar, R.P., De Jongh, B.M., Drijfhout, J.W., Schegget, J.T., Melief, C.J. and Kast, W.M., 1993. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. European journal of immunology, 23(9), pp.2242-2249.doi:10.1002/eji.1830230929
Noguchi, Y., Richards, E.C., Chen, Y.T. and Old, L.J., 1995. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proceedings of the National Academy of Sciences, 92(6), pp.2219-2223.doi:10.1073/pnas.92.6.2219
Mandelboim, O., Vadai, E., Fridkin, M., Katz-Hillel, A., Feldman, M., Berke, G. and Eisenbach, L., 1995. Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides. Nature medicine, 1(11), pp.1179-1183.doi:10.1038/nm1195-1179
Mayordomo, J.I., Zorina, T., Storkus, W.J., Zitvogel, L., Celluzzi, C., Falo, L.D., Melief, C.J., Ildstad, S.T., Kast, W.M., Deleo, A. and Lotze, M.T., 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature medicine, 1(12), p.1297.doi:10.1038/nm1295-1297
Fearon, E.R., Pardoll, D.M., Itaya, T., Golumbek, P., Levitsky, H.I., Simons, J.W., Karasuyama, H., Vogelstein, B. and Frost, P., 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell, 60(3), pp.397-403.doi:10.1016/0092-8674(90)90591-2
Golumbek, P.T., Lazenby, A.J., Levitsky, H.I., Jaffee, L.M., Karasuyama, H., Baker, M. and Pardoll, D.M., 1991. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science, 254(5032), pp.713-716.doi:10.1126/science.1948050
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hamada, H., Pardoll, D. and Mulligan, R.C., 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proceedings of the National Academy of Sciences, 90(8), pp.3539-3543.doi:10.1073/pnas.90.8.3539
Pardoll, D.M. and Topalian, S.L., 1998. The role of CD4+ T cell responses in antitumor immunity. Current opinion in immunology, 10(5), pp.588-594.doi:10.1016/S0952-7915(98)80228-8
Greenberg, P.D., Kern, D.E. and Cheever, M.A., 1985. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+, 2-T cells. Tumor eradication does not require participation of cytotoxic T cells. Journal of Experimental Medicine, 161(5), pp.1122-1134.doi:10.1084/jem.161.5.1122
Husmann, L.A. and Bevan, M.J., 1988. Cooperation between helper T cells and cytotoxic T lymphocyte precursors. Annals of the New York Academy of Sciences, 532(1), pp.158-169.doi:10.1111/j.1749-6632.1988.tb36335.x
Marchand, M., Punt, C.J.A., Aamdal, S., Escudier, B., Kruit, W.H.J., Keilholz, U., Håkansson, L., Van Baren, N., Humblet, Y., Mulders, P. and Avril, M.F., 2003. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. European Journal of Cancer, 39(1), pp.70-77.doi:10.1016/S0959-8049(02)00479-3
